Previous close | 0.6000 |
Open | 0.6000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 12.50 |
Expiry date | 2024-06-21 |
Day's range | 0.6000 - 0.6000 |
Contract range | N/A |
Volume | |
Open interest | 40 |
The addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.
NEWPORT BEACH, Calif., May 20, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal nasolabial fold (NLF) study of dermal filler products Evolysse™ Lift and Smooth. Data were presented at the 2024 SCALE Meeting on May 17, 2024, in Nashville.
On May 14, 2024, David Gill, Director at Evolus Inc (NASDAQ:EOLS), executed a sale of 10,361 shares of the company.